MRCP With Contrast for Elevated LFTs
For patients with unexplained elevated liver function tests, you should obtain MRCP WITH gadolinium contrast (MRI abdomen without and with IV contrast with MRCP), not MRCP alone. 1
The Evidence-Based Approach
The 2023 ACR Appropriateness Criteria provides clear guidance on this question. Contrast-enhanced MRI with MRCP is explicitly described as "the most useful imaging modality for evaluating the etiology of biliary obstruction" when biliary ductal dilatation is identified 1. The guidelines emphasize that contrast administration provides critical diagnostic advantages that non-contrast MRCP cannot deliver.
Why Contrast Matters
Contrast administration improves sensitivity for detecting:
- Acute cholangitis
- Hepatic metastases
- Primary sclerosing cholangitis
- Ischemic liver injury
- Portal hypertension sequelae 1
The contrast agent (particularly hepatobiliary agents) provides additional functional information through biliary excretion, helping identify the site and etiology of obstruction while simultaneously assessing liver function 1. This dual anatomic and functional assessment cannot be achieved with non-contrast MRCP alone.
The Algorithmic Approach
Start with ultrasound first - this is your initial imaging modality for elevated LFTs, particularly when alkaline phosphatase is elevated 1.
If ultrasound shows biliary ductal dilatation OR if ultrasound is negative but LFTs remain persistently elevated, proceed directly to MRI abdomen without and with IV contrast with MRCP 1.
What Non-Contrast MRCP Misses
While non-contrast MRCP can identify biliary obstruction, the ACR guidelines explicitly state it is "less sensitive than contrast-enhanced MRI" 1. The guidelines note that contrast-enhanced MRI with MRCP "enables triaging of patients to subsequent interventions" like ERCP, endoscopic ultrasound, or biopsy, serving as a procedural roadmap 1.
Research supports this: a 2017 study found that while non-contrast MRI with HASTE sequences showed similar accuracy for choledocholithiasis specifically 2, this narrow finding doesn't address the broader differential diagnosis of elevated LFTs where contrast provides crucial additional information about parenchymal disease, malignancy, and inflammatory conditions.
Common Pitfalls to Avoid
Don't order MRI without AND with contrast - the ACR guidelines state there is "no benefit from adding unenhanced images" when contrast is being given 1. Order the study as "MRI abdomen with IV contrast and MRCP" (which includes pre-contrast sequences by protocol).
Be aware of hepatobiliary contrast agent timing - if gadoxetic acid (Eovist/Primovist) is used, T2-weighted MRCP sequences must be obtained BEFORE contrast administration, as this agent decreases biliary signal intensity on T2 images 3. Most protocols account for this, but confirm with your radiology department.
Consider contraindications - if the patient has severe renal impairment (eGFR <30) or gadolinium allergy, non-contrast MRCP becomes your best option despite its limitations 1. In this scenario, accept that sensitivity will be reduced for certain diagnoses.
Special Population: Inflammatory Bowel Disease
If your patient has inflammatory bowel disease, the yield of MRCP increases substantially - one study found pathological MRCP findings in 36% of IBD patients with elevated LFTs versus only 14% in the general population 4. This makes contrast-enhanced MRCP particularly valuable in this subset.